Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
Revolution Medicines soared to a fresh all-time high on Monday, as investors cheered the stellar results from the clinical trial of its pancreatic cancer treatment, daraxonrasib. In an updated report, Revolution Medicines Inc. (NASDAQ:RVMD) said that Daraxonrasib recorded a median overall survival of 13.2 months versus only 6.7 months for chemotherapy. ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of 'World Bank of NK Cells' Photo by Anthony Shkraba on Pexels “Daraxonrasib as a targeted medicine delivered a dramatic improvement in overall survival in patients with previously treated metastatic pancreatic cancer compared to standard of care chemotherapy, consistent with earlier findings. These results represent a potentially transformative advance for patients and underscore daraxonrasib's potential to redefine the treatment landscape,” Revolution Medicines Inc. (NASDAQ:RVMD) Chairman and CEO Mark Goldsmith said. “We are moving with urgency toward global regulatory submi
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.MarketBeat
- After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]CNN
- After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]CNN
- Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 8-K
- 4/16/26 - Form 8-K
- RVMD's page on the SEC website